Patient engagement is widely recognised as essential to modern drug development, but measuring whether it actually influences decisions, priorities, and organisational behaviour remains one of the field’s hardest problems.
A new article from Spectrum Science’s Executive Director, Patient Engagement, Stephen O’Farrell explores this challenge directly: how pharmaceutical and biotech companies can move beyond activity metrics and satisfaction scores to track the influence patient insight has on real decisions. The piece introduces a focused, three-layered evaluation framework, covering process, outcome, and impact indicators, designed to cut through the noise of 100+ possible metrics to find the ones that genuinely reflect your strategy.
Read the full article “Where Patient Insight Meets Strategy: Measuring What Truly Matters”.
If you’re looking to turn patient insight into sharper strategy, stronger stakeholder alignment, and programmes that create measurable impact, Spectrum Science can help. Get in touch to explore how we can support your patient engagement goals.
Perspectives
Patient Engagement
A New Way of Thinking About Patient Activation
Patient Engagement
Turning Experience into Value: Europe’s Opportunity to Lead on Patient-Focused Medicines Development
Patient Engagement
Solving the patient engagement value equation
Medical Communications ,
Patient Engagement
Spectrum Science Communications awarded PIF TICK accreditation to become a ‘trusted information creator’
